All In Biotech

Drug Trial Radar · NCT06545474

Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)

Repetitive Transcranial Magnetic Stimulation (rTMS) as an Early Intervention in Major Depression (MD) Compared to Antidepressant Selective Serotonin Reuptake Inhibitor (SSRI) Medication (Early-TMS)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Sep 15, 2024

Primary completion

Jul 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
University Hospital TuebingenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
German Center for Mental Health
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this randomized multicentre phase 2 clinical trial is to compare the effects of rTMS and SSRI medication as early treatment of depression. In this two-stage, therapy response-adapted trial, 106 patients suffering from non-treatment resistant major depression (non-TR MD) will be randomized in Stage I to either 4 weeks bilateral theta burst stimulation (TBS) or 4 weeks antidepressant SSRI medication. The allocation to Stage II occurs therapy response-adapted. Patients receive either a maintenance treatment or a switch to the respective other treatment arm. The primary outcome is the comparison of the two study arms with regard to therapy response measured with the Montgomery-Asberg Depression Rating Scale (MADRS) after 4 weeks at the end of Stage I.

Conditions

  • Major Depressive Disorder

Interventions

  • bilateral theta burst stimulationDevice

    Each stimulation session consists of 600 stimuli applied in bursts of 3 pulses at 50 Hz, with an interstimulus interval of 200 ms. iTBS is administered 20 times for 2 seconds to the left dlPFC, with an intertrain interval of 8 seconds and cTBS continuously for 40 seconds to the right dlPFC in alternating order.

  • SSRI treatmentDrug

    Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. response rates after Stage ITime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Tuebingen

    Tübingen, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.